Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

December 8th, 2015 6:00 – 8:30 p.m.

1. Executive Session 6:00 - 6:30

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)
   - DUR Chair Election

3. DVHA Pharmacy Administration Updates 6:35 - 6:40
   - Updates

4. Medical Director Update 6:40 – 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 – 7:00
   - Clinical Criteria Review
     - Natpara® (parathyroid hormone)
   - Therapeutic Drug Classes/PDL 2016 Changes
     - Platelet Aggregation Inhibitor Intermittent Claudication
     - ADHD and Narcolepsy Cataplexy
     - Analgesics Long Acting
     - Anticoagulants, Injectables
     - Antidiabetics – Non Insulin
     - Antimigraine Triptans
     - Lipotropics
     - Multiple Sclerosis
     - Ophthalmics
     - Platelet Inhibitors
     - Pulmonary Agents
     - Renal Disease Phosphate Binders

6. RetroDUR/DUR 7:00 – 7:20
   - Testosterone Update
     - Discussion of using a Rank Order to target Physicians that are often prescribing Testosterone Products
   - Present multiple benzo analysis including sedative/hypnotic (Z drugs)
   - Appropriate Use of Asthma Controller Medications

7. Clinical Update: Drug Reviews 7:20 – 7:45
   (Public comment prior to Board action)
Abbreviated New Drug Reviews
- Fycompa® Tab (perampanel) (included in the class review)

Full New Drug Reviews
- Aptensio XR® Cap (methylphenidate extended-release)
- Glatopa® Inj (glatiramer)
- Invega Trinza® Extended-Release Inj (paliperidone)
- Irenka® Cap (duloxetine)
- Quixda XR® Cap (topiramate extended-release) (included in the class review)
- Stiolto Respimat® Inhaler (tiotropium & olodaterol)
- Tivorbex® Cap (indomethacin)

8. Therapeutic Drug Classes – Periodic Review
   (Public comment prior to Board action)
   - Anticonvulsants
   - Bladder Relaxant Preparations
   - BPH Agents
   - Epinephrine, Self-Injected
   - Hyperuricemia & Gout
   - IBS/SBS/Selected GI Agents
   - Smoking Deterrents

9. New Managed Therapeutic Drug Classes
   (Public comment prior to Board action)

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)

11. General Announcements
    Selected FDA Safety Alerts

Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density

Acetaminophen Tablets by Medline Industries: Recall - Mislabling with Incorrect Strength

FDA alerts prescribers and pharmacists to continue clozapine prescribing and dispensing if they encounter online Clozapine REMS certification issues

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
FDA Drug Safety Communication: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)

FDA Drug Safety Communication: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone

FDA Drug Safety Communication: FDA cautions about dose confusion and medication error with antibacterial drug Avycaz (ceftazidime and avibactam)

FDA Drug Safety Communication: FDA evaluating the risks of using the pain medicine tramadol in children aged 17 and younger

CDEF conversation: Safe medicine disposal options
http://www.fda.gov/drugs/newsevents/ucm464197.htm

Auvi-Q (epinephrine injection, USP): Recall - Potential Inaccurate Dosage Delivery

FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death

12. Adjourn 8:30